The company said, “Turning our focus to 2024, we’re enthusiastic about CVRx‘s future and the ongoing commercial adoption of Barostim. With a strong foundation, an exceptional leadership team, and consistent execution of our strategy over the last two years, we are confident in our ability to attract a high-caliber CEO. This individual will play a crucial role in executing our strategic plans and driving future commercial growth. Serving as CEO of CVRx has been an incredible experience and privilege, and I look forward to continuing to contribute to the Company’s success through this transition.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CVRX:
- Cvrx, Inc. (CVRX) Q4 Earnings Cheat Sheet
- CVRx price target raised to $31 from $30 at Canaccord
- CVRx price target raised to $35 from $32 at Lake Street
- CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024
- CVRx price target raised to $30 from $24 at Craig-Hallum
